CClinicalTrials.gg
CompletedNCT03450265Updated Apr 6, 2020

Hemopatch Compared to TachoSil in Postoperative Air Leak Duration After Pulmonary Resection

An interventional study of Hemopatch and Tachosil in Air Leak From Lung, sponsored by Baxter Healthcare Corporation. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-06.

Sponsored by Baxter Healthcare Corporation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized, controlled study, with the primary objective to demonstrate non-inferiority of Hemopatch compared to TachoSil in postoperative air leak duration after pulmonary resection, and with the secondary objective of evaluating the safety of Hemopatch compared to TachoSil.

02

Conditions studied

  • Air Leak From Lung
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Preoperative-

  • Patients, 18 years or older at the time of signing the informed consent form (ICF), undergoing elective pulmonary resections (lobectomy, segmentectomy, or wedge resection), either through open thoracotomy or through Visually Assisted Thoracotomy surgery (VATS)
  • Patients or legally authorized representatives, who are able to give IC after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period
  • If female of child-bearing potential, patient will present with a negative blood/urine pregnancy test, and will agree to employ adequate birth control measures for the duration of the study

Intraoperative-

  • Patients with grade 1 or 2 (Macchiarini scale) air leakage after primary stapling and limited suturing

Exclusion criteria

Exclusion Criteria:

Preoperative-

  • Patients who had previous lung surgery (on the same side)
  • Patients with an active, florid infection
  • Patients who have received chemotherapy within the previous 3 weeks.
  • Patients who have received radiation therapy within the previous 4 weeks.
  • Patients with known hypersensitivity to the components of the investigational product and control (human fibrinogen, human thrombin, collagen of any origin, NHS-PEG)
  • Patients undergoing emergency surgery
  • Female patients of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period
  • Female patients who are nursing
  • Patients with exposure to another investigational drug or device clinical trial within 30 days prior to enrollment or anticipated in the 30 day study period till the End of study visit.
  • Patient has a clinically significant concurrent medical condition (e.g. concomitant illness, drug/alcohol abuse) that, in the opinion of the investigator, could adversely affect patient's safety and/or compliance with study procedures
  • Patient is a family member or employee of the investigator

Intraoperative-

  • Patients with serious complications during surgery, including the need for adhesiolysis, and pneumonectomy.
  • Patients who were treated with any surgical sealant
  • Major intraoperative complications that require resuscitation or deviation from the planned surgical procedure
  • Patients with any other intraoperative findings identified by the surgeon that may preclude the conduct of the study procedure
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Hemopatch

    Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.

    Device: Hemopatch

  • Active comparator
    TachoSil

    Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.

    Device: Tachosil

Interventions

  • DeviceHemopatch

    Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.

  • DeviceTachosil

    Applied according to the current instruction for use (IFU).

05

What researchers measure

Primary outcomes

  1. Duration of postoperative air leakage

    Time frame: Day 1 to Day 30

Secondary outcomes

  1. Incidence of intraoperative treatment failure

    Time frame: Day 1

  2. Incidence of patients with prolonged air leakage defined as air leakage > 5 Days

    Time frame: Day 5 to Day 30

  3. Number of additional procedures needed

    Type of procedures include chest drainage, re-operation, respiratory assistance, and blood transfusion

    Time frame: Day 1 to Day 30

  4. Time to chest tube removal

    Time frame: Day 1 to Day 30

  5. Time in surgery (minutes) from incision to closure

    Time frame: Day 1

  6. Length of stay in hospital (days)

    Time frame: Day 1 to Day 30

  7. Number of unplanned interventions

    Time frame: Day 1 to Day 30

  8. Incidence of pre-defined postoperative Adverse Events of Special Interest (AESIs)

    Pre-defined AEs include Pneumothorax, Bronchopleural fistula, Emphysema (subcutaneous and mediastinal), Pleural effusions, Postoperative respiratory failure, Empyema, Allergic reactions in reasonable temporal relationship with the product application

    Time frame: Day 1 to Day 30

  9. Number of patches used intra-operatively

    Time frame: Day 1

06

Study locations

14 sites
  • Baxter Investigational Site
    Catania, 95123, Italy
  • Baxter Investigational Site
    Milan, 20141, Italy
  • Baxter Investigational Site
    Padova, 35128, Italy
  • Baxter Investigational Site
    Pisa, 56124, Italy
  • Baxter Investigational Site
    Rome, 144, Italy
  • Baxter Investigational Site
    Rome, 151, Italy
  • Baxter Investigational Site
    Rome, 168, Italy
  • Baxter Investigational Site
    Seville, Andalucia 41009, Spain
  • Baxter Investigational Site
    Madrid, Community Of Madrid 28006, Spain
  • Baxter Investigational Site
    Madrid, Community Of Madrid 28040, Spain
  • Baxter Investigational Site
    Madrid, Community Of Madrid 28933, Spain
  • Baxter Investigational Site
    Madrid, Getafe 28905, Spain
  • Baxter Investigational Site
    Alzira, Valencia 46600, Spain
  • Baxter Investigational Site
    Madrid, 28046, Spain
07

Registry details

Key details

Study ID
NCT03450265
Lead sponsor
Baxter Healthcare Corporation
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Jun 26, 2018
Primary completion
Jul 9, 2019
Completion
Jul 9, 2019
Last update
Apr 6, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion